CN109908140A - 生物素治疗多发性硬化的用途 - Google Patents

生物素治疗多发性硬化的用途 Download PDF

Info

Publication number
CN109908140A
CN109908140A CN201910026016.2A CN201910026016A CN109908140A CN 109908140 A CN109908140 A CN 109908140A CN 201910026016 A CN201910026016 A CN 201910026016A CN 109908140 A CN109908140 A CN 109908140A
Authority
CN
China
Prior art keywords
biotin
multiple sclerosis
drug
purposes
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910026016.2A
Other languages
English (en)
Chinese (zh)
Inventor
F.塞德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Original Assignee
Assistance Publique - Hôpitaux de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris filed Critical Assistance Publique - Hôpitaux de Paris
Publication of CN109908140A publication Critical patent/CN109908140A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910026016.2A 2012-07-26 2013-04-29 生物素治疗多发性硬化的用途 Pending CN109908140A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1257254A FR2993780B1 (fr) 2012-07-26 2012-07-26 Methode de traitement de la sclerose en plaque
FR12/57254 2012-07-26
US13/644,615 2012-10-04
US13/644,615 US8835487B2 (en) 2012-07-26 2012-10-04 Method of treating multiple sclerosis
CN201380039687.3A CN104602689A (zh) 2012-07-26 2013-04-29 生物素治疗多发性硬化的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380039687.3A Division CN104602689A (zh) 2012-07-26 2013-04-29 生物素治疗多发性硬化的用途

Publications (1)

Publication Number Publication Date
CN109908140A true CN109908140A (zh) 2019-06-21

Family

ID=47294963

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910026016.2A Pending CN109908140A (zh) 2012-07-26 2013-04-29 生物素治疗多发性硬化的用途
CN201380039687.3A Pending CN104602689A (zh) 2012-07-26 2013-04-29 生物素治疗多发性硬化的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380039687.3A Pending CN104602689A (zh) 2012-07-26 2013-04-29 生物素治疗多发性硬化的用途

Country Status (25)

Country Link
US (5) US8835487B2 (cg-RX-API-DMAC7.html)
EP (2) EP2729143B1 (cg-RX-API-DMAC7.html)
JP (1) JP6208235B2 (cg-RX-API-DMAC7.html)
KR (1) KR101967502B1 (cg-RX-API-DMAC7.html)
CN (2) CN109908140A (cg-RX-API-DMAC7.html)
AU (1) AU2013295370B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015001562A2 (cg-RX-API-DMAC7.html)
CA (1) CA2879434C (cg-RX-API-DMAC7.html)
CY (1) CY1116304T1 (cg-RX-API-DMAC7.html)
DK (2) DK2857019T3 (cg-RX-API-DMAC7.html)
EA (1) EA030478B1 (cg-RX-API-DMAC7.html)
ES (3) ES2532364T3 (cg-RX-API-DMAC7.html)
FR (1) FR2993780B1 (cg-RX-API-DMAC7.html)
HK (1) HK1207583A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150260T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024558T2 (cg-RX-API-DMAC7.html)
IL (1) IL236790A (cg-RX-API-DMAC7.html)
LT (1) LT2857019T (cg-RX-API-DMAC7.html)
ME (1) ME02060B (cg-RX-API-DMAC7.html)
PL (1) PL2729143T3 (cg-RX-API-DMAC7.html)
PT (2) PT2857019T (cg-RX-API-DMAC7.html)
RS (1) RS53893B1 (cg-RX-API-DMAC7.html)
SI (2) SI2729143T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500057B (cg-RX-API-DMAC7.html)
WO (1) WO2014016003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
KR102494401B1 (ko) * 2015-02-13 2023-02-02 유니마테크 가부시키가이샤 함불소 공중합체 및 이것을 유효 성분으로 하는 표면개질제
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2017086835A1 (ru) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты)
RU2638803C2 (ru) * 2016-06-09 2017-12-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки биотина с замедленным высвобождением и способ их получения
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
GB2568849B (en) * 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
RU2639488C1 (ru) * 2017-04-06 2017-12-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция, содержащая биотин, и способ ее получения
WO2020102203A1 (en) * 2018-11-13 2020-05-22 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
CN112076310A (zh) * 2019-06-14 2020-12-15 苏州融析生物科技有限公司 一种治疗多发性硬化的药物组合物及其制备
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
CA3157712C (en) 2020-01-01 2024-01-23 Jotiram PALKAR Synergistic nutritional compositions for enhancing atp efficiency

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG109164A (bg) * 2005-05-25 2006-11-30 Райна Щонова Състав от растителен произход
WO2011124571A1 (fr) * 2010-04-06 2011-10-13 Assistance Publique - Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3609165A (en) 1968-07-19 1971-09-28 Research Corp 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes
JPH0995448A (ja) 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US6664039B1 (en) 1998-10-14 2003-12-16 California Institute Of Technology Methods and compositions for modulating neurodegeneration
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE19903241A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
US20050256178A1 (en) 2002-08-23 2005-11-17 Eggersdorfer Manfred L Novel nutraceutical compositions comprising boitin
CA2501021C (en) 2002-09-30 2011-02-22 Daiichi Pharmaceutical Co., Ltd. Pantethine-containing particulate
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
IL162288A0 (en) * 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
EP2515863A2 (en) 2009-12-23 2012-10-31 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG109164A (bg) * 2005-05-25 2006-11-30 Райна Щонова Състав от растителен произход
WO2011124571A1 (fr) * 2010-04-06 2011-10-13 Assistance Publique - Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.ANAGNOSTOULI等: "1-31-03 Biotin in CSF and serum in patients with multiple sclerosis", 《JOURNAL OF THE NEUROLOGICAL SCIENCES》 *
刘焯霖等: "《神经遗传病学》", 30 April 2002, 人民卫生出版社 *

Also Published As

Publication number Publication date
SI2729143T1 (sl) 2015-05-29
ES2811074T3 (es) 2021-03-10
AU2013295370A1 (en) 2015-02-19
US20190117626A1 (en) 2019-04-25
BR112015001562A2 (pt) 2017-07-04
CA2879434A1 (en) 2014-01-30
SI2857019T1 (sl) 2020-10-30
HRP20150260T1 (hr) 2015-05-08
US20140348920A1 (en) 2014-11-27
RS53893B1 (sr) 2015-08-31
HK1207583A1 (en) 2016-02-05
ES2626079T3 (es) 2017-07-21
IL236790A (en) 2017-09-28
CY1116304T1 (el) 2017-02-08
ES2532364T3 (es) 2015-03-26
US20140030331A1 (en) 2014-01-30
LT2857019T (lt) 2020-09-10
KR101967502B1 (ko) 2019-04-09
ME02060B (me) 2015-05-20
PT2857019T (pt) 2020-07-24
DK2729143T3 (en) 2015-03-23
SMT201500057B (it) 2015-05-05
AU2013295370B2 (en) 2017-03-02
US20160324830A1 (en) 2016-11-10
DK2857019T3 (da) 2020-08-17
US8835487B2 (en) 2014-09-16
PT2729143E (pt) 2015-03-16
EP2857019A1 (en) 2015-04-08
CN104602689A (zh) 2015-05-06
WO2014016003A1 (en) 2014-01-30
US10201528B2 (en) 2019-02-12
HUE024558T2 (hu) 2016-02-29
EA030478B1 (ru) 2018-08-31
PL2729143T3 (pl) 2015-05-29
EP2857019B1 (en) 2020-05-27
FR2993780A1 (fr) 2014-01-31
EA201590270A1 (ru) 2015-11-30
FR2993780B1 (fr) 2015-02-13
US9351961B2 (en) 2016-05-31
EP2729143B1 (en) 2014-12-31
KR20150042799A (ko) 2015-04-21
US20190117625A1 (en) 2019-04-25
CA2879434C (en) 2019-04-23
EP2729143A1 (en) 2014-05-14
JP2015522630A (ja) 2015-08-06
JP6208235B2 (ja) 2017-10-04

Similar Documents

Publication Publication Date Title
AU2013295370B2 (en) Use of biotin for the treatment of multiple sclerosis
EP2442832A1 (en) Compositions and methods for treatment of multiple sclerosis
US20190314342A1 (en) Method for treating demyelinating neuropathy with biotin
KR20120050512A (ko) 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료
JP2018515447A (ja) 軸索障害の処置用のパルテノライドおよびその誘導体
TW200916091A (en) Neramexane for the treatment of nystagmus
Lakshmikuttyamma et al. Antipsychotic agents
CN111743894A (zh) 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用
HK40008598A (en) Use of biotin for the treatment of multiple sclerosis
JP2023539391A (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
US20190134006A1 (en) Method of treating multiple sclerosis
NZ735528B2 (en) Biotin for treating demyelinating neuropathies
HK1116079A (en) 1-aminocyclohexane-derivatives for the treatment of multiple sclerosis emotional lability and pseudobulbar affect

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008598

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190621